Pharmacokinetic and Pharmacodynamic Investigations of ION-353382, a Model Antisense Oligonucleotide: Using Alpha-2-Macroglobulin and Murinoglobulin Double-Knockout Mice-Reference-Cited by-同舟云学术

Pharmacokinetic and Pharmacodynamic Investigations of ION-353382, a Model Antisense Oligonucleotide: Using Alpha-2-Macroglobulin and Murinoglobulin Double-Knockout Mice

Published:2016-08 Issue:4 Volume:26 Page:223-235
ISSN:2159-3337
Container-title:Nucleic Acid Therapeutics
language:en
Short-container-title:Nucleic Acid Therapeutics

Author:

Shemesh Colby S.¹,Yu Rosie Z.¹,Gaus Hans J.²,Seth Punit P.³,Swayze Eric E.³,Bennett Frank C.⁴,Geary Richard S.⁵,Henry Scott P.⁶,Wang Yanfeng¹

Affiliation:

1. Department of Pharmacokinetics and Clinical Pharmacology, Ionis Pharmaceuticals, Carlsbad, California.

2. Department of Structural Biology, Ionis Pharmaceuticals, Carlsbad, California.

3. Department of Medicinal Chemistry, Ionis Pharmaceuticals, Carlsbad, California.

4. Department of Research Biology, Ionis Pharmaceuticals, Carlsbad, California.

5. Department of Clinical Development, Ionis Pharmaceuticals, Carlsbad, California.

6. Department of Toxicology, Ionis Pharmaceuticals, Carlsbad, California.

Publisher

Mary Ann Liebert Inc

Subject

Drug Discovery,Genetics,Molecular Biology,Molecular Medicine,Biochemistry

Link

http://www.liebertpub.com/doi/pdf/10.1089/nat.2016.0607

Reference37 articles.

1. Proteinase Inhibitory Spectrum of Mouse Murinoglobulin and α-Macroglobulin

2. Alpha-2-macroglobulin: A physiological guardian

3. Identification of Four Genes Coding for Isoforms of Murinoglobulin, the Monomeric Mouse α2-Macroglobulin: Characterization of the Exons Coding for the Bait Region

4. The primary sequence and the subunit structure of mouse alpha-2-macroglobulin, deduced from protein sequencing of the isolated subunits and from molecular cloning of the cDNA

Cited by 32 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Localization of unlabeled bepirovirsen antisense oligonucleotide in murine tissues using in situ hybridization and CARS imaging;RNA;2023-07-17

2. DNA-Based Nanomaterials as Drug Delivery Platforms for Increasing the Effect of Drugs in Tumors;Cancers;2023-04-05

3. Enhancing the Effectiveness of Oligonucleotide Therapeutics Using Cell-Penetrating Peptide Conjugation, Chemical Modification, and Carrier-Based Delivery Strategies;Pharmaceutics;2023-04-03

4. Drug Metabolism and Pharmacokinetics of Antisense Oligonucleotide Therapeutics: Typical Profiles, Evaluation Approaches, and Points to Consider Compared with Small Molecule Drugs;Nucleic Acid Therapeutics;2023-04-01

5. Time Is a Critical Factor When Evaluating Oligonucleotide Therapeutics in hERG Assays;Nucleic Acid Therapeutics;2023-04-01